Key Insights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

75.0%

3 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed with results

Key Signals

3Total

P 1 (2)

P 2 (1)

Terminated3

Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

A Biomarker Screening Protocol for Participants With Solid Tumors

A Study to Investigate LYL797 in Adults With Solid Tumors

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Showing all 4 trials